- Home
- PFG vs ROIV Comparison
PFG vs ROIV Comparison
Compare PFG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFG | ROIV |
|---|---|---|
| Founded | 1879 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0B | 26.1B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PFG | ROIV |
|---|---|---|
| Price | $111.89 | $36.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $94.30 | $28.94 |
| AVG Volume (30 Days) | 1.2M | ★ 5.5M |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $15,625,500,000.00 | $8,260,000.00 |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | $4.97 | $744.61 |
| P/E Ratio | $57.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $77.90 | $11.62 |
| 52 Week High | $116.61 | $37.97 |
Technical Indicators
Market Signals| Indicator | PFG | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 57.40 |
| Support Level | $111.00 | $33.01 |
| Resistance Level | $112.45 | $37.00 |
| Average True Range (ATR) | 2.02 | 1.19 |
| MACD | -0.52 | 0.04 |
| Stochastic Oscillator | 21.77 | 69.59 |
Price Performance
Historical ComparisonAbout PFG Principal Financial Group Inc
Principal Financial Group Inc is a financial services provider. It offers various financial products and services including retirement, asset management, and workplace benefits and protection solutions to individuals and institutional clients. The company, along with its subsidiaries, operates in the following reportable segments; Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. Maximum revenue is generated from the Retirement and Income Solutions segment which provides workplace savings and retirement solutions, banking, trust and custodial services, individual variable annuities (including RILAs), pension risk transfer, and investment services to businesses, their employees, and other individuals.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.